Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7448243 | 0.77 | — | — | |
| SCHEMBL25134507 | 0.77 | — | — | |
| SCHEMBL6124723 | 0.75 | — | — | |
| SCHEMBL17980313 | 0.75 | — | — | |
| SCHEMBL22728952 | 0.73 | CYP19A1 (0.39) | TSHRNPSR1 | |
| Hydrochloric Acid SCHEMBL26618937 | 0.73 | CYP19A1 (0.33) | TSHRNPSR1 | |
| SCHEMBL28056833 | 0.72 | TSHR (0.31) | TSHRNPSR1 | |
| SCHEMBL14378068 | 0.71 | TSHR (0.34) | TSHRNPSR1 | |
| SCHEMBL21426014 | 0.69 | CYP19A1 (0.31) | — | |
| SCHEMBL7431209 | 0.68 | OTUD7B (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | INFINITY PHARMACEUTICALS, INC. | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060022-A1 | TREATMENT OF CANCERS USING PI3 KINASE ISOFORM MODULATORS | PIK3CA, MCL1, PIK3CB | TSHR 2434/4885NPSR1 4441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.